<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>19(10)</volume><submitter>Fang JY</submitter><funding>Takeda Development Center Americas Inc.</funding><pubmed_abstract>Fabry disease, an X-linked lysosomal storage disorder caused by galactosidase α (GLA) gene mutations, exhibits diverse clinical manifestations, and poses significant diagnostic challenges. Early diagnosis and treatment are crucial for improved patient outcomes, pressing the need for reliable biomarkers. In this study, we aimed to identify miRNA candidates as potential biomarkers for Fabry disease using the KingFisher™ automated isolation method and NanoString nCounter® miRNA detection assay. Clinical serum samples were collected from both healthy subjects and Fabry disease patients. RNA extraction from the samples was performed using the KingFisher™ automated isolation method with the MagMAX mirVanaTM kit or manually using the Qiagen miRNeasy kit. The subsequent NanoString nCounter® miRNA </pubmed_abstract><journal>PloS one</journal><pagination>e0301733</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11515968</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Exploring the diagnostic potential of miRNA signatures in the Fabry disease serum: A comparative study of automated and manual sample isolations.</pubmed_title><pmcid>PMC11515968</pmcid><pubmed_authors>Ayyadurai S</pubmed_authors><pubmed_authors>Sugimoto H</pubmed_authors><pubmed_authors>Qian MG</pubmed_authors><pubmed_authors>Fang JY</pubmed_authors><pubmed_authors>Pybus AF</pubmed_authors></additional><is_claimable>false</is_claimable><name>Exploring the diagnostic potential of miRNA signatures in the Fabry disease serum: A comparative study of automated and manual sample isolations.</name><description>Fabry disease, an X-linked lysosomal storage disorder caused by galactosidase α (GLA) gene mutations, exhibits diverse clinical manifestations, and poses significant diagnostic challenges. Early diagnosis and treatment are crucial for improved patient outcomes, pressing the need for reliable biomarkers. In this study, we aimed to identify miRNA candidates as potential biomarkers for Fabry disease using the KingFisher™ automated isolation method and NanoString nCounter® miRNA detection assay. Clinical serum samples were collected from both healthy subjects and Fabry disease patients. RNA extraction from the samples was performed using the KingFisher™ automated isolation method with the MagMAX mirVanaTM kit or manually using the Qiagen miRNeasy kit. The subsequent NanoString nCounter® miRNA </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-07-06T03:16:48.72Z</modification><creation>2025-04-06T14:21:11.164Z</creation></dates><accession>S-EPMC11515968</accession><cross_references><pubmed>39466827</pubmed><doi>10.1371/journal.pone.0301733</doi></cross_references></HashMap>